GlassScriptPhysician profile
Jade Abad
NPI 1942662358
$1,575.28
in general payments reported to CMS, 2019-2025
22 companies · $101 in 2025
The $101 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $137 · 2020: $345 · 2021: $167 · 2022: $696 · 2023: $60.26 · 2024: $69.27 · 2025: $101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $230.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $188.07 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $178.38 | 2019-2022 | |
| Seagen INC. | $174.99 | 2019-2022 | |
| Abbvie INC. | $170.56 | 2024-2025 | |
| Global Blood Therapeutics, INC. | $128.39 | 2020-2022 | |
| Janssen Scientific Affairs, LLC | $112.50 | 2022 | |
| Amgen INC. | $95.00 | 2020 | |
| Apellis Pharmaceuticals, INC. | $88.66 | 2022 | |
| Incyte Corporation | $73.99 | 2022 | |
| Merck Sharp & Dohme LLC | $63.99 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $55.31 | 2021 | |
| Celgene Corporation | $46.70 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $41.83 | 2023 | Imbruvica |
| Genentech USA, INC. | $32.49 | 2022 | |
| Karyopharm Therapeutics INC. | $23.89 | 2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $22.85 | 2022 | |
| Foundation Medicine, INC. | $18.43 | 2023 | |
| Sobi, INC | $16.75 | 2022 | |
| Astellas Pharma US INC | $16.05 | 2022 | |
| Genzyme Corporation | $13.26 | 2020 | |
| Boston Scientific Corporation | $13.19 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jade Abad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.